Page 152 - 80_01

Avances
en
artritis
reumatoide

82.
Ma,
M.H.;
Scott,
I.C.;
Kingsley,
G.H.;
Scott,
D.L.
Remission
in
early
rheumatoid
arthritis.
J

Rheumatol
37,
1444-­-1453
(2010).

83.
Jayakumar,
K.;
Norton,
S.;
Dixey,
J.;
James,
D.;
Gough,
A.;
Williams,
P.;
et
al.
Sustained
clinical

remission
in
rheumatoid
arthritis:
prevalence
and
prognostic
factors
in
an
inception

cohort
of
patients
treated
with
conventional
DMARDS.
Rheumatology
(Oxford)
51,
169-­-
175
(2012).

84.Shammas,
R.M.;
Ranganath,
V.
K.;
Paulus,
H.E.
Remission
in
rheumatoid
arthritis.

CurrRheumatol
Rep
12,
355-­-362
(2010).

85.
Brown,
A.K.;
Conaghan,
P.G.;
Karim,
Z.;
Quinn,
M.A.;
Ikeda,
K.;
Peterfy,
C.G.;
et
al.
An

explanation
for
the
apparent
dissociation
between
clinical
remission
and
continued

structural
deterioration
in
rheumatoid
arthritis.ArthritisRheum
58,
2958-­-2967
(2008).

86.
Maesea,
J.;
García
De
Yébenes,
M.
J.;
Carmona,
L.;
Hernández-­-García,
C.;
el
Grupo
de
Estudio

emAR
II.
Estudio
sobre
el
manejo
de
la
artritis
reumatoide
en
España
(emAR
II).

Características
clínicas
de
los
pacientes.
Reumatol
Clin
8,
236-­-242
(2012).

87.
Niedermann,
K.;
de
Bie,
R.
A.;
Kubli,
R.;
Ciurea,
A.;
Steurer-­-Stey,
C.;
Villiger,
P.
M.;
et
al.

Effectiveness
of
individual
resource-­-oriented
joint
protection
education
in
people
with

rheumatoid
arthritis:
a
randomized
controlled
trial.
Patient
Educ
Couns
82,
42-­-48
(2011).

88.
Steultjens,
E.
M.;
Dekker,
J.;
Bouter,
L.
M.;
van
Schaardenburg,
D.;
van
Kuyk,
M.
A.;
Van
den

Ende,
C.
H.
Occupational
therapy
for
rheumatoid
arthritis.
Cochrane
Database
Syst

Rev1,(2004).
Disponible
en:
http://dx.doi.org/10.1002/14651858.CD003114.pub2.

89.
Hewlett,
S.;
Ambler,
N.;
Almeida,
C.;
Cliss,
A.;
Hammond,
A.;
Kitchen,
K.;
et
al.
Self-­-
management
of
fatigue
in
rheumatoid
arthritis:
a
randomised
controlled
trial
of
group

cognitive-­-behavioural
therapy.
Ann
Rheum
Dis70,
1060-­-1067
(2011).

90.
Hagen,
K.
B.;
Dagfinrud,
H.;
Moe,
R.
H.;
Østerås,
N.;
Kjeken,
I.;
Grotle,
M.;
et
al.
Exercise

therapy
for
bone
and
muscle
health:
an
overview
of
systematic
reviews.
BMC
Medicine
10,

(2012).
Disponible
en:
http://www.biomedcentral.com/1741-­-7015/10/167.

91.
Tokuyama,
S.;
Nakamoto,
K.
Current
Topics
Lipid
Mediators
and
Pain
Signaling

Unsaturated
Fatty
Acids
and
Pain.
BiolPharm
Bull
34,
1174-­-1178
(2011).

92.
Yeoh,
N.;
Burton,
J.
P.;Suppiah,
P.;Reid,
G.;Stebbings,
S.The
role
of
the
microbiome
in

rheumatic
diseases.
Curr
Rheumatol
Rep
15,
314
(2013).
Disponible
en:
http//dx.doi.org/

10.1007/s11926-­-012-­-0314-­-y.

93.
Saag,
K.
G.
Short-­-term
and
Long-­-term
Safety
of
Glucocorticoids
in
Rheumatoid
Arthritis.

Bull
NYU
HospJt
Dis
70(Suppl
1),S21-­-25
(2012).

94.
Cheng,
O.
T.;
Souzdalnitski,
D.;Vrooman,
B.;
Cheng,
J.
Evidence
based
knee
injections
for
the

management
of
arthritis.
Pain
Med
June
13,
740-­-753
(2012).

95.
Baggott,
J.
E.;Morgan,
S.
L.
Methotrexate
catabolism
to
7-­-hydroxy
methotrexate
in

rheumatoid
arthritis
alters
drug
efficacy
and
retention
and
is
reduced
by
folic
acid

supplements.
Arthritis
Rheum
60,
2257-­-2261
(2009).

96.
O'Dell,
J.
R.;
Mikuls,
T.
R.;
Taylor,
T.
H.;
Ahluwalia,
V.;
Brophy,
M.;
Warren,
S.
R.;
et
al.

Therapies
for
active
rheumatoid
arthritis
after
metotrexate
failure.
N
Engl
J
Med
369,
307-­-
318
(2013).

97.
Smolen,
J.
S.;
Aletaha,
D.
Forget
personalized
medicine
and
focus
on
abating
disease

activity.
Ann
Rheum
Dis
72,
3-­-6
(2013).

98.
Rosman,
Z.;
Shoenfeld,
Y.;
Zandman-­-Goddard,
G.
Biologic
therapy
for
autoimmune
diseases:

an
update.
BMC
Medicine11,
88
(2013).
Disponible
en:

http://www.biomedcentral.com/1741-­-7015/11/88

99.
Malviya,
G.;
Salemi,
S.;
Laganà,
B.;
PicchiantiDiamanti,
A.;
D’Amelio,
R.;
Signore,
A.
Biological

Therapies
for
Rheumatoid
Arthritis:
Progress
to
Date.
Bio
Drugs
27,
329-­-345
(2013).

100.
Smolen,
J.
S.;
Emery,
P.
Infliximab:
12
years
of
experience.
Arthritis
Res
Ther13
(Suppl
1),

S2
(2011).
Disponible
en:
http://arthritis-­-research.com/supplements/13/S1/S2.

101.
Al-­-Shakarchi,
I.;
Gullick,
N.J.;
Scott,
D.
L.
Current
perspectives
on
tocilizumab
for
the

treatment
of
rheumatoid
arthritis:
a
review.
Patient
Preference
and
Adherence
7,
653-­-666

(2013).

102.
Smolen,
J.
S.;
Schoels,
M.
M.;
Nishimoto,
N.;
Breedveld,
F.C.;
Burmester,
G.R.;
Dougados,
M.

et
al.
Consensus
statement
on
blocking
the
effects
of
interleukin-­-6
and
in
particular
by

interleukin-­-6
receptor
inhibition
in
rheumatoid
arthritis
and
other
inflammatory

conditions.
Ann
Rheum
Dis
72,
482-­-92
(2013).
Disponible
en:

http://dx.doi.org/10.1136/annrheumdis-­-2012-­-202469.

149